In his weekly clinical update Dr. Griffin\xa0discusses\xa0the infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave,\xa0virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants, antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants,\xa0comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans,\xa0time to negative PCR conversion among high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated by Sotrovimab or Nirmatrelvir,\xa0COVID drug Paxlovid was hailed as a game-changer, what happened?,\xa0the Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice,\xa0SARS-CoV-2 infection and persistence in the human body and brain at autopsy, long-term cardiovascular outcomes of COVID-19, and how heart-disease risk soars after COVID \u2014 even with a mild case.
Subscribe (free):\xa0Apple Podcasts,\xa0Google Podcasts,\xa0RSS,\xa0emailBecome a\xa0patron\xa0of\xa0TWiV!
Links for this episodeIntro music is by\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv